alexa Role of Genetic Testing in Lung Transplantation; Prediction of Inflammation | Open Access Journals
ISSN: 2157-7412
Journal of Genetic Syndromes & Gene Therapy
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Role of Genetic Testing in Lung Transplantation; Prediction of Inflammation

Mohamed SA Mohamed*

University of Cologne, Deutz-Kalker Str, Cologne, Germany

*Corresponding Author:
Mohamed SA Mohamed
University of Cologne, Deutz-Kalker Str, Cologne, Germany
Tel: 01625706493
E-mail: Mohammed.shehatta1@gmail.com

Received date: May 12, 2016; Accepted date: Jun 01, 2016; Published date: Jun 08, 2016

Citation: Mohamed MSA (2016) Role of Genetic Testing in Lung Transplantation; Prediction of Inflammation. J Genet Syndr Gene Ther 7:298. doi:10.4172/2157-7412.1000298

Copyright: © 2016 Mohamed MSA. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Genetic Syndromes & Gene Therapy

Abstract

While the genetic matching between the donor and the recipient is essential for the success of the transplant procedure, there are other genetic factors that have the potential to significantly influence the clinical outcome. In this paper, the light is shed on this notion from a relatively new point of view.

Keywords

IL6; IL10; Genetic polymorphisms/mutations; Solid organ transplants

Introduction

Due to the increased incidence of end-stage lung diseases that lead to pulmonary failure, lung transplant becomes a frequent life-saving intervention. Unfortunately, there is a high incidence rate of primary graft dysfunction and failure after transplant. Research is progressing strongly in many directions to improve the clinical outcome of lung transplant.

Interleukin-6 (IL-6) is a pro-inflammatory cytokine and an antiinflammatory myokine. In humans, it is encoded by the IL6 gene [1]. IL-6 is produced mainly by the T cells and the macrophages of the lung, bone marrow, spleen, lymph nodes, brain and skin. Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) is the main regulator of IL-6 gene expression, which increases in all cases of tissue injury and inflammation [2].

IL-6 is also secreted by the vascular smooth muscles as a proinflammatory cytokine, however, IL-6 processes an indirect antiinflammatory effects through the antagonization of TNF-alpha and IL-1, and the activation of IL-10 [3].

IL-10 is another cytokine, but with anti-inflammatory actions. It down regulates the expression of cytokines in the T helper-1 cells, and the major histocompatibility class II antigens and costimulatory molecules on the surface of macrophages. Moreover, IL-10 antgonizes the activity of NF-κB [4].

Accordingly, the balance between IL-6 and IL-10 can affect the prognosis of any inflammatory condition, including the ischemic reperfusion injury and the graft- host interaction. Hence, the ratio between both cytokines has the potential to predict the prognosis of lung transplant and the incidence of post-transplant graft failure [5]. A high IL-6/IL-10 ratio post-transplant was found to be associated with severe primary graft dysfunction and 20 fold increased relative risk of death [5].

Clinical and experimental implication of the principle

The Torono team for lung transplant, which is one of the leading teams in this regard, has already developed a chip to assess the expression levels of mRNAs of certain genes in graft biopsy, as markers for the prognosis of lung transplant. This includes the expression levels of IL-6 and IL-10. This technology is reliable and takes between 20-30 min, which can be performed while the graft on ex vivo perfusion [6].

As the graft biopsies deal with the graft after death of the donor (pre -implantation), in order to assess the expression levels of the IL-6 and IL-10, in addition to other biomarkers, this might be affected by several variabls, such as the cause of death of the donor and the associated conditions, the degree of the ischemic reperfusion injury, to which the garft has been exposed, and can be also attenuated through the application of graft conditioning techniques, such as preconditioning. This might not be able to reflect the post-transplant in vivo graft condition regarding the targeted biomarkers.

Moreover, there are imprinted genetic factors that could be considered earlier, by the time the donor makes his discision for donation. Although such imprinted genetic factors might also be reflected during the pre-implantation assessment, it would be much better to identify these risk factors ealier, so that, the precious time and money could be saved. Some of those genetics imprints lie in the mutations/polymorphisms that result in over expression of IL-6 and or defective IL-10.

There are 5 splice variants of IL-6, the standard is a 212 amino acids (aa) and the others are 252aa, 136aa, 189aa, 198aa and 122aa. Certain polymorphisms, such as the homozygous IL6-174G allele, are associated with decreased function of IL-6, reflected as an increased susceptibility to sepsis [7]. Accordingly, polymorphisms and or mutations, associated with the increased IL-6 expression, will ultimately result in high IL-6/IL-10 ratio and the subsequent primary graft dysfunction, whereas those associated with defective IL-6 expression would have the potential to provide a safer donor graft.

On the other side, loss- or decrease-of-function mutations of the IL-10 gene will lead to similar consequences. IL-10 receptor A polymorphisms, rs2228054 and rs2228055, have been reported to give the upper hand to the development of the inflammatory bowel disease [8]. A similar reaction could be expected in the lung graft.

Following these principles, two polymorphisms of INF-γ and IL-6 genes were reported to be associated with faster development of chronic lung allograft dysfunction (CLAD) following transplant [9,10]. Moreover, genetic polymorphysims/mutations of the Toll-Like Receptor family have a reported impact on the development of inflammation and rejection/CLAD after lung transplant [11-13].

Although some studies failed to correlate CLAD with the known genetic polymorphysims of TNF-α, TGF-β 1, and IL-10, those studies were concentrating on the genetic polymorphisms of the recepients rather than the donor (graft) [14,15].

Conclusion

As the source of the graft cytokines is mainly the resident leukocytes, a preliminary assessment for the increased IL-6 and/or the decreased/defective IL-10 mutations/polymorphisms (in addition to any other relevant genetic markers of inflammation) in the leukocytes of a blood sample can provide a valuable information about the suitability of the potential donor (Figure 1).

genetic-syndromes-gene-therapy-diagrammatic-illustration

Figure 1: Diagrammatic illustration of the role of the genetic testing of the inflammatory mutations during lung transplant according to the present recommendation and the reported experiences.

This notion is applicable not only for lung transplant, but also for other solid organs transplants. Accordingly, clinical studies to assess the genetic profile of the genes of interest prior to donation, can provide the evidence based association with the rate of success of the transplant procedure and the frequencies of the post-transplant complications. This could be of great value, at least to mark the future grafts as “relatively high risk”, which would indicate the application of especial immunomodulatory intervensions during lung transplant according to the present recommendation and the reported experiences.

Conflicts of Interest

The intellectual properties included in this manuscript belong solely to the author. Reproduction or use of any of them requires the written permission of the author.

No funding was provided for the development of this work.

The author welcomes funding cooperation for experimental and clinical studies.

References

 

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 8401
  • [From(publication date):
    June-2016 - Oct 24, 2017]
  • Breakdown by view type
  • HTML page views : 8318
  • PDF downloads :83

Review summary

  1. Noah Crawford
    Posted on Sep 23 2016 at 12:46 pm
    The author presented evidences mainly collected from published papers to show that a preliminary assessment for the increased IL-6 and/or the decreased/defective IL-10 mutations/polymorphisms in the leukocytes of a blood sample can provide valuable information about the suitability of the potential donor.
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

agrifoodaquavet@omicsonline.com

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

clinical_biochem@omicsonline.com

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

business@omicsonline.com

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

chemicaleng_chemistry@omicsonline.com

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

environmentalsci@omicsonline.com

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

engineering@omicsonline.com

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

generalsci_healthcare@omicsonline.com

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

genetics_molbio@omicsonline.com

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

immuno_microbio@omicsonline.com

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

omics@omicsonline.com

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

materialsci@omicsonline.com

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

mathematics_physics@omicsonline.com

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

medical@omicsonline.com

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

neuro_psychology@omicsonline.com

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

pharma@omicsonline.com

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

social_politicalsci@omicsonline.com

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords